
曾鴻泰
副教授
免疫學
腫瘤免疫學
分子生物學
腫瘤生物學
- 聯絡電話
- 電子郵件信箱
htay11@cgmh.org.tw
腫瘤細胞與免疫細胞在腫瘤微環境中的交互作用容易促成腫瘤發展,主要原因在於腫瘤細胞衍生之訊息易於塑造免疫抑制環境的發展而壓制對抗腫瘤之免疫反應。藉由免疫檢查點抑制劑 (immune checkpoint inhibitor)恢復對抗腫瘤之免疫活性而達到抑制腫瘤生長的效果。儘管如此,對於免疫檢查點抑制劑療法展現療效的比例並不高。plasminogen activator inhibitor 1 (PAI-1)是參與血栓與動脈硬化的重要蛋白,也被發現在許多腫瘤組織中有過度表現。在我們的研究中發現PAI-1可以調控腫瘤細胞表面的PD-L1,抑制PAI-1促使腫瘤細胞表面PD-L1增加而提升對免疫檢查點抑制劑敏感度,進而改善免疫抑制劑療法。
另一方面,相對於免疫檢查點抑制劑,化療仍是臨床常使用的療法。我們也發現腫瘤細胞經由自噬作用分泌出PAI-1改變了微環境的免疫細胞因而對化療產生抗性。我們也持續探討腫瘤衍生物質與免疫細胞活性之連結,期望有助於開發新穎腫瘤免疫治療方式。
Selected recent publications (Pubmed Search)
(† Contributed equally to the article; * Correspondence author of the article)
Lee WC, Leu S, Su CH, Tain YL, Wu KLH, Hsu CN, Tzeng HT*. Tadalafil Ameliorates Chronic Ischemia-Associated Bladder Overactivity in Fructose-Fed Rats by Exerting Pelvic Angiogenesis and Enhancing p-eNOS Expression. International Journal of Molecular Sciences, 26(3):1363 (2025)
Tzeng HT, Lee WC. Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity. Nutrients, 16(9):1388 (2024)
Tzeng HT, Huang YJ. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity. International Journal of Molecular Sciences, 24(5):4422 (2023)
Tzeng HT, Chyuan IT*, Lai JH*. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. Biochemical Pharmacology, 193:114760 (2021)
Tzeng HT, Chyuan IT*. Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications. Journal of the Formosan Medical Association, 120(9):1667-1675 (2021)
Tzeng HT, Yang JL, Tseng YJ, Lee CH, Chen WJ, Chyuan IT. Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation. Cancers, 13(6):1253 (2021)
Tseng YJ, Lee CH, Chen WY, Yang JL, Tzeng HT*. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade. Journal of Investigative Dermatology, 141(11):2690-2698.e6 (2021)
Peng JM, Chen WY, Cheng JH, Luo JW, Tzeng HT*. Dysregulation of Cytoskeleton Remodeling Drives Invasive Leading Cells Detachment. Cancers, 13(22):5648 (2021)
Chen WY, Li LC, Wu YH, Yang JL, Tzeng HT*. Emerging Roles of Interleukin-33-responsive Kidney Group 2 Innate Lymphoid Cells in Acute Kidney Injury. International Journal of Molecular Sciences, 21(4):1544 (2020)
Tzeng HT, Chyuan IT, Chen WY. Shaping of Innate Immune Response by Fatty Acid Metabolite Palmitate. Cells, 8(12):1633 (2019)
|
陳韋如研究助理
|
黃瑱芳研究助理
|
洪春姿
|
|
黃宜婷工讀生
|
|
|
EDUCATION:
2007 – 2014 Ph.D.
Graduate Institute of Immunology, College of Medicine,
National Taiwan University, Taipei, Taiwan
PROFESSIONAL EXPERIENCE:
2018/8 ~ present Assistant Professor
Institute for Translational Research in Biomedicine,
Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung, Taiwan
2014/8 ~ 2018/7 Postdoctoral Research Fellow
Department of Pharmacology, College of Medicine,
National Cheng Kung University, Tainan, Taiwan
AWARDS AND RESEARCH SUPPORT:
2017 The third Prize (oral presentation in English), Autumn Camp 2017, The Taiwan Society for
Biochemistry and Molecular Biology
2017 The Second Prize (Thematic oral presentation), 32th Joint Annual Conference of Biomedical
Science (JACBS)
2016 The First Prize (oral presentation), 31th Annual Meeting of Toxicology Society of Taiwan
2016 Travel Grant, International Academic Conference, Ministry of Science and Technology
2012 Travel Grant, Oversea International Academic Conference, Ministry of Education
2012 Travel Grant, aim for the top University Project to the National Taiwan University
2012 Excellent paper Award (oral presentation), The Chinese Society of Immunology
2011 Excellent paper Award (oral presentation), The Chinese Society of Immunology
2010 Excellent paper Award (oral presentation), The Chinese Society of Immunology
RESEARCH INTERESTS:
1. Viral immunology of infectious disease
2. Regulation of T cell activation in cancer
3. Development of immunotherapy for cancer treatment




